# Human Rating Form — GDgpt Clinical Utility Evaluation

> **Instructions**: Rate each question on D1-D5 (1=Poor, 3=Adequate, 5=Excellent).
> Fill in the table below. Use same rubric as the LLM judge.
> Return this file after completion.

## Rubric Summary
- **D1 Factual Accuracy**: Are gene/pathway/drug claims correct?
- **D2 Completeness**: Are key evidence items covered?
- **D3 Traceability**: Are claims attributed to specific sources/edges?
- **D4 Clinical Safety**: Does it acknowledge uncertainty vs. fabricate?
- **D5 Coherence**: Is it logically structured and readable?

---
## Question 1: `pcqa_21285043`
**Q**: Is there a strong association between BRCA1 gene mutation and ovarian carcinoma?

### System A (GDgpt)
```
BRCA1 is ASSOCIATED_WITH hereditary breast ovarian cancer syndrome (HBOC) and INVOLVED_IN DNA repair pathways, including "Defective DNA double strand break response due to BARD1 loss of function," "Defective DNA double strand break response due to BRCA1 loss of function," and "G2/M DNA damage checkpoint," per the knowledge graph. These pathways are critical for maintaining genomic stability, and mutations in BRCA1 can impair these mechanisms, increasing the risk of genomic instability, a hallmark of cancer development. BRCA1 mutations in HBOC are also ASSOCIATED_WITH the phenotype "abnormal fallopian tube morphology," which may have tissue-specific implications for ovarian carcinoma development. While no KG evidence directly links BRCA1 mutations to ovarian carcinoma, this connection is wi
```

### System B (GPT-4o)
```
Yes, there is a strong association between BRCA1 gene mutations and ovarian carcinoma. Germline mutations in the BRCA1 gene significantly increase the lifetime risk of developing ovarian cancer, with estimates ranging from 39% to 59% by the age of 70. BRCA1 mutations lead to defective homologous recombination repair of DNA double-strand breaks, resulting in genomic instability and increased susceptibility to malignancy. High-grade serous ovarian carcinoma (HGSOC) is the most common histological subtype associated with BRCA1 mutations. Identification of BRCA1 mutations has important therapeutic implications, including the potential use of PARP inhibitors and tailored management strategies. 

For the most recent or specific data, external literature or databases would need to be consulted.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 2: `pcqa_fb9a2cc6`
**Q**: What genetic diseases can be caused by cancers with PKD1 mutations?

### System A (GDgpt)
```
**PKD1**, which encodes polycystin-1, is known to regulate cellular signaling, proliferation, and tissue architecture [LLM-inferred]. However, no direct evidence from the knowledge graph (KG) connects **PKD1** to any disease or pathway, including cancer or genetic diseases. Diseases such as **Schizophrenia** are ASSOCIATED_WITH pathways like the **RAF/MAP kinase cascade**, **G alpha (i) signaling events**, and **Neutrophil degranulation**, involving genes such as **IL3**, **PDGFRB**, **GRIN1**, and **GSTP1**. Similarly, **Familial prostate carcinoma** is ASSOCIATED_WITH the **Neutrophil degranulation** pathway, driven by genes like **B2M**, **ALOX5**, and **GSTP1**, while **Hereditary breast-ovarian cancer syndrome** is ASSOCIATED_WITH the **Interleukin-4 and Interleukin-13 signaling** pat
```

### System B (GPT-4o)
```
PKD1 mutations are primarily associated with **polycystic kidney disease (PKD)**, specifically autosomal dominant polycystic kidney disease (ADPKD). However, PKD1 mutations are not typically linked to cancers. Instead, somatic mutations in PKD1 have been occasionally identified in certain cancers, such as **renal cell carcinoma (RCC)**, but their direct pathogenic role in cancer remains uncertain and under investigation.

It is worth noting that PKD1 mutations may indirectly contribute to tumorigenesis in the kidney by creating a microenvironment of chronic cyst formation and tissue remodeling, which could predispose individuals to **renal neoplasms**. However, the data on PKD1 mutations as oncogenic drivers is currently limited and requires further research.

If additional clarification o
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 3: `pcqa_da2476bf`
**Q**: What genetic mutations are present in endocervical adenocarcinoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
Endocervical adenocarcinoma is commonly associated with specific genetic mutations and alterations. The most frequent mutations include:

1. **KRAS**: Mutations in the KRAS oncogene are observed in a significant subset of cases.
2. **PIK3CA**: Alterations in the PIK3CA gene, which encodes a subunit of PI3K, are common and often lead to activation of the PI3K/AKT pathway.
3. **TP53**: Mutations in the tumor suppressor gene TP53, though less frequent than in squamous cell carcinoma, can occur.
4. **ARID1A**: Loss-of-function mutations in ARID1A, involved in chromatin remodeling, may be seen.
5. **STK11**: Mutations in STK11 (also known as LKB1) are less common but have been reported.
6. **ERBB2 (HER2)**: Amplification or overexpression of ERBB2 can occur in a subset of cases.
7. **SMAD4**: M
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 4: `pcqa_d0b052f8`
**Q**: What are the genetic mutations in lung adenocarcinoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Lung adenocarcinoma is frequently driven by specific genetic mutations that can be used as therapeutic targets or prognostic markers. The most common genetic alterations include:

1. **EGFR (Epidermal Growth Factor Receptor) Mutations**: Found in ~10–50% of cases (higher in non-smokers and East Asian populations). Common mutations include exon 19 deletions and the L858R point mutation in exon 21.

2. **KRAS Mutations**: Present in ~25–30% of cases, particularly in smokers. Common mutations occur at codons 12, 13, or 61.

3. **ALK (Anaplastic Lymphoma Kinase) Rearrangements**: Occur in ~3–7% of cases, often involving EML4-ALK fusion.

4. **ROS1 Rearrangements**: Found in ~1–2% of cases, structurally similar to ALK fusions.

5. **BRAF Mutations**: Present in ~1–3% of cases. The V600E mutatio
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 5: `pcqa_f888cf0a`
**Q**: What drugs can treat cancers with TERT mutations?

### System A (GDgpt)
```
The **TERT** gene, which encodes the catalytic subunit of telomerase, is targeted by **Grn163l**, **Tertomotide**, and **Zidovudine** as confirmed by the knowledge graph (KG: TERT–TARGETS–Grn163l, TERT–TARGETS–Tertomotide, TERT–TARGETS–Zidovudine; sources=DrugBank & NCBI). Telomerase is crucial for maintaining telomere length, a process critical for cellular replication and immortality [LLM-inferred]. Mutations in **TERT** are frequently observed in cancers and are associated with increased telomerase activity, enabling tumor progression and sustained growth [LLM-inferred]. Among the drugs, **Grn163l** functions as a telomerase inhibitor aimed at suppressing telomerase activity, while **Tertomotide** is a cancer vaccine potentially stimulating immune responses against telomerase-expressing
```

### System B (GPT-4o)
```
Currently, there are no FDA-approved drugs specifically targeting TERT (telomerase reverse transcriptase) mutations. However, cancers with TERT promoter mutations often exhibit telomerase activation, contributing to cellular immortality, and several therapeutic strategies are being explored:

1. **Telomerase Inhibitors**:
   - **Imetelstat**: A direct telomerase inhibitor, currently in clinical trials, has shown promise in some cancers dependent on telomerase activity.

2. **ATR Inhibitors**:
   - TERT mutations are linked to telomere dysfunction, leading to replication stress. ATR inhibitors (e.g., **ceralasertib**, **elimusertib**) exploit this vulnerability in preclinical and early clinical studies.

3. **Immune Checkpoint Inhibitors**:
   - TERT promoter mutations have been associated 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |
